Globus Medical (GMED)
(Delayed Data from NYSE)
$72.05 USD
+2.37 (3.40%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $72.05 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
C Value C Growth B Momentum C VGM
Price, Consensus and EPS Surprise
GMED 72.05 +2.37(3.40%)
Will GMED be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GMED based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for GMED
Globus Medical's (GMED) Lateral Interbody Portfolio Gets New Launch
Zimmer Biomet's (ZBH) Latest Deal to Expand Its Hip Portfolio
GMED: What are Zacks experts saying now?
Zacks Private Portfolio Services
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
Here's Why Globus Medical (GMED) is a Strong Momentum Stock
Here's Why Globus Medical (GMED) is a Strong Growth Stock
Other News for GMED
Globus Medical Launches ADIRA? XLIF? Plate System
Looking Into Globus Medical's Recent Short Interest
Small-cap and mid-cap Health Care has room to rally - Roth MKM
Analysts Offer Insights on Healthcare Companies: Globus Medical (GMED), Avidity Biosciences (RNA) and Veeva Systems (VEEV)
Buy Rating Affirmed for Globus Medical Despite FDA Warning: Manageable Regulatory Challenges Ahead